Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Editas Medicine Inc | EDIT | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 5.35 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 5.35 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 5.28 - 11.91 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 5.35 | USD |
Editas Medicine Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 438.52M | 81.81M | - | 78.12M | -153.22M | -1.87 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Editas Medicine News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EDIT Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 5.60 | 5.92 | 5.28 | 5.49 | 1,854,944 | -0.25 | -4.46% |
| 1 Month | 7.46 | 7.52 | 5.28 | 6.28 | 1,705,735 | -2.11 | -28.28% |
| 3 Months | 7.07 | 11.58 | 5.28 | 7.88 | 1,946,901 | -1.72 | -24.33% |
| 6 Months | 6.52 | 11.69 | 5.28 | 8.66 | 1,894,905 | -1.17 | -17.94% |
| 1 Year | 7.83 | 11.91 | 5.28 | 8.66 | 1,837,750 | -2.48 | -31.67% |
| 3 Years | 36.98 | 73.025 | 5.28 | 18.30 | 1,753,116 | -31.63 | -85.53% |
| 5 Years | 26.92 | 99.95 | 5.28 | 25.59 | 1,529,269 | -21.57 | -80.13% |
Editas Medicine Description
| Editas Medicine Inc is a gene-editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company's only operating segment is developing and commercializing genome editing technology. |
